

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/579,620	
Sheet	1	of	2	Filing Date	April 19, 2007
				First Named Inventor	Shawn DeFrees
				Group Art Unit	1654
				Examiner Name	Heard, Thomas S.
				Attorney Docket Number	101961-5145-US01

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Kind Code (if known)		
	2004/0063911	A1	DeFrees et al.	04-01-2004
	2005/0118672	A1	DeFrees et al.	06-02-2005
	2006/0024286	A1	Glidden	02-02-2006
	2007/0027068	A1	DeFrees et al.	02-01-2007
	2007/0105755	A1	DeFrees et al.	05-10-2007
	2008/0015142	A1	DeFrees et al.	01-17-2008
	4,879,236		Smith et al.	11-07-1989
	5,147,788		Page et al.	09-15-1992
	5,194,376	A	Kang	03-16-1993
	5,635,603		Hansen et al.	06-03-1997
	5,646,113		Attie et al.	07-08-1997
	6,531,121	B2	Brines et al.	03-11-2003
	7,138,371	B2	DeFrees et al	11-21-2006
	7,338,933	B2	DeFrees et al.	03-04-2008
	7,405,198	B2	DeFrees et al	07-29-2008

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Country Code	Number	Kind Code (if known)	
	EP 1428878		A1	Bavand et al.
	WO 90/08164		A1	Garlick, et al.
	WO 90/08823		A1	Parcelis, et al.
	WO 96/21469		A1	Harris, et al.
	WO 99/45964		A1	Harris, et al.
	WO 00/26354		A1	Olsen, et al.
	WO 02/092619		A2	Loh, et al.
	WO 02/53580		A2	The Kenneth S. Warren Institute, Inc.
	WO 04/033651		A2	De Frees, et al.
	WO 04/10327		A2	Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V.
	WO 04/103275		A2	DeFrees
	WO 04/96148		A2	The Kenneth S. Warren Institute, Inc.
	WO 05/121331		A2	Neose Technologies, Inc.
	WO 05/25606		A1	Warren Pharmaceuticals, Inc.; The Kenneth S. Warren Institute, Inc.
	WO 05/67601		A2	Neose Technologies, Inc.
	WO 05/70138		A2	Neose Technologies, Inc.
	WO 06/031811		A2	De Frees, et al.
	WO 06/14349		A2	The Kenneth S. Warren Institute, Inc.

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND COMMENTS OR REQUESTS FOR EXPLANATIONS TO THE EXAMINER. COMMUNICATIONS WITH EXAMINERS SHOULD BE MADE THROUGH THE OFFICE PAPERS.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet

2

of

2

Application Number	10/579,620
Filing Date	April 19, 2007
First Named Inventor	Shawn DeFrees
Group Art Unit	1654
Examiner Name	Heard, Thomas S.
Attorney Docket Number	101961-5145-US01

	WO 06/14466	A2	The Kenneth S. Warren Institute, Inc.	02-09-2006	
	WO 06/74279	A1	Neose Technologies, Inc.	07-13-2006	
	WO 06/78645	A2	Neose Technologies, Inc.	07-27-2006	
	WO 08/11633	A2	Neose Technologies, Inc.	01-24-2008	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T.
	Alam et al., 1998. Journal of Biotechnology. 65: 183-190.	
	Bedard et al., 1994. Cytotechnology 15:129-138.	
	Bennett et al., 1998. J. Biol. Chem. 273:30472-30481.	
	Bennett et al., 1999. FEBS Letters 460:226-230.	
	Bork (2000) Genome Research 10:398-400.	
	Bork et al. (1996) Trends in Genetics 12(10): 425-427.	
	Brenner (1999) Trends in Genetics 15(4) 132-133.	
	Doerks et al. (1998) Trends in Genetics 14(6): 248-250.	
	Fritz et al., 2004. PNAS 101(43):15307-15312.	
	Fritz et al., 2006. J. Biol. Chem. 281(13):8613-8619.	
	Gilbert et al., 1996. Cytotechnology 22:211-216.	
	Hagen et al., 1999. J. Biol. Chem. 274:27867-27874.	
	Hagen et al., 1999. J. Biol. Chem. 274:6797-6803.	
	Hagen et al., 2001. J. Biol. Chem. 276:17395-17404.	
	Harris et al., Abstracts of Papers of the American Chemical Society, 1991, V 201, APR, P 64-POLY, page 154-155.	
	Hassan et al., 2000. J. Biol. Chem. 275:38197-38205.	
	Hink et al., 1991. Biotechnology Progress 7:9-14.	
	Ikonomou et al., 1991. In Vitro Cell. Dev. Biol.-Animal 37:549-559.	
	Inlow, et al., 1989. J. Tissue Culture Meth. 12:13-16.	
	Lau et al. (1999) Journal of Biotechnology 75:105-115.	
	Licari P. et al., 1992. Biotechnology and Bioengineering 39(4):432-441.	
	Licari P. et al., 1992. Biotechnology and Bioengineering 39(9):932-944.	
	Ngo et al. (1994) "The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox" pp. 433-440 and 492-495.	
	Reis et al., 1991. Biotechnology and Bioengineering 38:413-422.	
	Sandberg et al., 2000. Seminars in Hematology 38(2):4-12.	
	Schlaeger, E., 1996. Cytotechnology 20:57-70.	
	Schwientek et al., 2002. J. Biol. Chem. 277:22623-22638.	
	Skolnick et al. (2000) Trends in Biotech. 18(1): 34-39.	
	Smith et al. (1997) Nature Biotechnology 15:1222-1223.	
	Tenno et al., 2002. J. Biol. Chem. 277(49):47088-96.	
	Wells (1990) Biochemistry 29(37): 8509-8517.	

DB2/21049889.1

Examiner Signature	/Scarlett Goon/	Date Considered	06/28/2010
--------------------	-----------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./